01/07/2024
This noninferiority study examines outcomes of rituximab-abbs versus reference rituximab in patients with diffuse large B-cell lymphoma in an integrated health care system in California, USA.
Background Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is one of the first line treatments for diffuse large B-cell lymphoma (DLBCL). Rituximab comprises most of the treatment cost for this regimen; therefore, biosimilars, such as rituximab-abbs are crucial to....